Thyroid Hormone Receptor-β Agonists Monitoring Bundle

What Is the Thyroid Hormone Receptor-β Agonists Drug Class?

THR-β agonists selectively activate the thyroid hormone receptor beta isoform, which predominates in the liver and drives hepatic fatty-acid oxidation, lipid clearance, and fibrosis-related gene expression. Resmetirom is the only approved member of this class as of mid-2025. The selective hepatic targeting avoids the cardiac and bone adverse effects that limit non-selective thyroid hormone use.

Mechanism of Action

Thyroid hormone receptors exist as two main isoforms: alpha (THR-α, dominant in heart and bone) and beta (THR-β, dominant in liver). Endogenous triiodothyronine (T3) activates both, which is why exogenous thyroid hormone causes atrial fibrillation and accelerated bone loss at supraphysiologic doses. Resmetirom binds THR-β with roughly 28-fold selectivity over THR-α, concentrates in hepatocytes via organic anion-transporting polypeptides, and upregulates genes that accelerate mitochondrial fatty-acid oxidation and reduce de novo lipogenesis [1].

The downstream effect is a measurable reduction in hepatic triglyceride content, LDL-C, non-HDL-C, and apolipoprotein B, all of which are relevant in MASH patients who carry high cardiovascular risk [2].

Disease Context: MASH and the Treatment Gap

MASH affects an estimated 6.5% of U.S. Adults, roughly 16.5 million people, and progresses to cirrhosis in 15 to 25% of cases over two decades [3]. Before resmetirom's approval, no drug carried an FDA indication specifically for MASH fibrosis. Weight-loss strategies (GLP-1 receptor agonists, bariatric surgery) reduce hepatic steatosis but have not yet earned a fibrosis-specific label in MASH. The approval of resmetirom closed that gap for the F2, F3 fibrosis population.

Regulatory Pathway and Approval Basis

The FDA granted resmetirom accelerated approval based on histologic endpoints from the MAESTRO-NASH trial (N=966) [4]. The agency required two co-primary endpoints to be met simultaneously: NASH resolution without fibrosis worsening, and fibrosis improvement by at least one stage without NASH worsening. Both were met at 52 weeks. A post-marketing confirmatory trial (MAESTRO-NASH OUTCOMES) is ongoing to verify survival benefit.

Baseline Assessment Before Starting Resmetirom

Every prescriber must complete a structured pre-treatment workup. Skipping baseline labs makes it impossible to interpret on-treatment changes and creates medico-legal exposure.

Required Baseline Laboratory Tests

The FDA prescribing information and the American Association for the Study of Liver Diseases (AASLD) MASH guidance specify the following [5, 6]:

| Test | Rationale | |------|-----------| | ALT, AST | Establish hepatic inflammation baseline; detect pre-existing elevation | | Total bilirubin, direct bilirubin | Assess synthetic reserve; elevation may signal decompensation | | Alkaline phosphatase (ALP) | Cholestatic component screening | | Albumin, INR/PT | Hepatic synthetic function; F4 exclusion support | | Lipid panel (LDL-C, TG, HDL-C, non-HDL-C) | Resmetirom lowers LDL-C 15 to 26%; baseline needed for cardiovascular risk tracking | | TSH (with reflex free T4) | Exclude pre-existing thyroid disease; resmetirom may suppress TSH modestly | | Serum hCG (urine hCG acceptable) | Mandatory pregnancy exclusion before first dose | | Complete metabolic panel | Renal function, electrolytes, glucose | | Hepatitis B surface antigen, anti-HCV | Rule out viral liver disease as primary etiology | | Liver biopsy report or validated FIB-4/elastography | Confirm F2, F3 fibrosis staging for on-label prescribing |

Resmetirom is not approved for F0, F1 or F4 (cirrhosis). Prescribing outside the F2, F3 window is off-label and carries undefined benefit-risk in those populations [7].

Biliary Imaging at Baseline

Cholelithiasis occurred in 10.3% of resmetirom-treated patients (80 mg and 100 mg pooled) vs. 4.9% placebo over 52 weeks in MAESTRO-NASH [4]. A baseline right-upper-quadrant ultrasound is strongly recommended to document pre-existing gallstones, assess gallbladder wall, and establish a reference point if biliary symptoms develop on therapy. The prescribing information lists cholelithiasis and cholecystitis as identified risks requiring clinical vigilance [7].

Pregnancy Prevention Program

Resmetirom caused fetal harm at doses below the human therapeutic exposure in animal studies and carries a contraindication in pregnancy [7]. Women of childbearing potential must use effective contraception (two forms, or one highly reliable method such as an IUD or hormonal implant) starting at least one cycle before the first dose. Confirm negative pregnancy status within 48 hours of initiating treatment.

On-Treatment Monitoring Schedule

Structured follow-up protects patients and generates the documentation needed for continued prescribing. The schedule below synthesizes the resmetirom prescribing information, AASLD MASH guidance, and the Endocrine Society's 2024 statement on thyromimetic agents [5, 7, 8].

Week 4 Visit

The week-4 visit is the first safety gate.

Labs to order:

• ALT, AST, total bilirubin
• TSH (resmetirom can modestly suppress TSH in some patients)
• Serum or urine hCG (women of childbearing potential)

Clinical review:

• Symptoms of cholelithiasis (right-upper-quadrant pain, nausea after fatty meals)
• Drug-drug interactions added since baseline (see CYP2C8 section)
• Tolerability (diarrhea is the most common GI adverse event: 25.9% resmetirom vs. 13.2% placebo in MAESTRO-NASH) [4]

If ALT rises above 3x the upper limit of normal (ULN) from a baseline that was already <3x ULN, hold dosing and investigate. Do not simply reduce dose without first excluding competing hepatotoxic causes.

Week 12 Visit

The week-12 visit evaluates early biochemical response and confirms ongoing safety.

Labs to order:

• Full liver panel (ALT, AST, ALP, total bilirubin, albumin)
• Lipid panel (LDL-C reduction of 15 to 26% should be visible by week 12) [9]
• TSH with reflex free T4 if TSH was suppressed at week 4
• hCG (women of childbearing potential)

Dose up-titration assessment: The approved dose is weight-based at initiation. A dose increase from 80 mg to 100 mg is not described in the current label as a standard up-titration step; the weight cut-off (100 kg) determines which dose is used from day one. If a patient crosses the 100-kg threshold after starting at 80 mg, clinical judgment should guide dose review [7].

Week 24 and Every 24 Weeks Thereafter

The 24-week visit is the efficacy and safety steady-state checkpoint.

Labs to order:

• Full liver panel
• Lipid panel
• Fasting glucose and HbA1c (most MASH patients have type 2 diabetes or metabolic syndrome)
• TSH annually after the 24-week TSH is within normal limits
• hCG monthly throughout therapy (women of childbearing potential)

Non-invasive fibrosis reassessment: Vibration-controlled transient elastography (FibroScan) or MRI-proton density fat fraction (MRI-PDFF) can document hepatic steatosis regression. No consensus exists on mandatory re-biopsy timing outside a clinical trial, but AASLD suggests re-biopsy consideration at 48 to 72 weeks for clinical decision-making in patients not showing biochemical improvement [5].

Liver Safety: Thresholds and Dose Modification Rules

Hepatotoxicity signals require a clear decision algorithm. The one below is drawn from the resmetirom prescribing information and FDA Drug Safety Communication [7, 10].

ALT/AST Elevation Algorithm

| Finding | Action | |---------|--------| | ALT/AST <3x ULN, asymptomatic | Continue; recheck in 4 weeks | | ALT/AST 3 to 5x ULN, no symptoms, bilirubin normal | Withhold dose; recheck in 1 to 2 weeks; resume if resolves to <3x ULN | | ALT/AST >5x ULN or any elevation + bilirubin >2x ULN | Permanently discontinue; urgent hepatology referral | | Hy's Law criteria (ALT >3x ULN + bilirubin >2x ULN + no other cause) | Permanently discontinue; report to FDA MedWatch |

Bilirubin elevation in combination with transaminase elevation (Hy's Law) is the signal for potential drug-induced liver injury (DILI) with potential for fatal outcome. The FDA Guidance on Drug-Induced Liver Injury explicitly names Hy's Law as the threshold for discontinuation [10].

Distinguishing DILI from MASH Flare

MASH itself causes ALT/AST elevation. A transaminase rise on resmetirom does not automatically signal DILI. Consider:

• Timing: DILI typically peaks within the first 12 weeks.
• Pattern: Hepatocellular pattern (ALT predominant) vs. Cholestatic (ALP/bilirubin predominant).
• Competing causes: New alcohol use, added hepatotoxic drugs, biliary obstruction from new cholelithiasis.
• Response to dechallenge: A 50% decline in ALT within 8 days of stopping the drug supports DILI over disease progression.

Hepatology co-management is appropriate when the etiology is unclear [11].

Thyroid Function Monitoring

Selective THR-β agonism can suppress pituitary TSH secretion to some degree because the pituitary expresses both THR-α and THR-β. In MAESTRO-NASH, TSH suppression below the normal range occurred in a small fraction of patients and was generally mild and reversible [4].

TSH Suppression: What to Do

If TSH falls below 0.4 mIU/L on resmetirom:

1. Confirm the result with a free T4 measurement.
2. Exclude other causes: new exogenous thyroid hormone, iodine load, pituitary pathology.
3. If free T4 is within normal limits and the patient is asymptomatic, continue resmetirom with TSH recheck in 8 weeks.
4. If free T4 is elevated or the patient has tachycardia, palpitations, or tremor, hold resmetirom and consult endocrinology.

Patients taking levothyroxine for hypothyroidism may need dose reduction if resmetirom produces additive THR-β stimulation. Recheck TSH 6 weeks after any levothyroxine adjustment [8].

Pre-Existing Thyroid Disease

The MAESTRO-NASH trial excluded patients with uncontrolled thyroid disease [4]. Use clinical judgment before prescribing resmetirom to patients with poorly controlled hyperthyroidism or Graves' disease. Euthyroid patients on stable levothyroxine were included in MAESTRO-NASH and can receive resmetirom with enhanced TSH monitoring [7].

Drug Interactions: The CYP2C8 and Transporter Network

Resmetirom is primarily metabolized by CYP2C8 and is a substrate of P-glycoprotein (P-gp) and organic anion transporting polypeptide 1B (OATP1B). These interactions matter because most MASH patients are on polypharmacy [12].

High-Priority Drug Interactions

| Interacting Drug/Class | Mechanism | Clinical Action | |-----------------------|-----------|-----------------| | Gemfibrozil (strong CYP2C8 inhibitor) | Increases resmetirom exposure ~2.5-fold | Contraindicated combination | | Rifampin (strong CYP2C8 inducer) | Reduces resmetirom exposure significantly | Avoid; if unavoidable, no dose guidance exists | | Cyclosporine (OATP1B inhibitor) | Increases resmetirom exposure | Avoid or monitor closely | | Statins (OATP1B substrates: rosuvastatin, atorvastatin) | Resmetirom inhibits OATP1B, raising statin AUC | Limit rosuvastatin to 10 mg/day; avoid high-dose atorvastatin | | Warfarin | Resmetirom may increase anticoagulant effect via hepatic CYP2C9 modulation | Check INR within 2 weeks of starting resmetirom |

The FDA prescribing information for resmetirom provides full interaction tables [7]. The Liverpool Drug Interaction Group also maintains a regularly updated interaction checker relevant for HIV/HCV co-infected patients.

Statin Co-Prescribing Nuance

Because resmetirom itself lowers LDL-C by 15 to 26% at 52 weeks [9], some patients on high-intensity statins may overshoot their LDL-C target. Check a lipid panel at week 12 and consider de-intensifying statin therapy if LDL-C falls below 40 mg/dL (a level associated with adverse effects in some observational data) [13].

Special Populations

Renal Impairment

No dose adjustment is required for mild-to-moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²). Resmetirom has not been studied in severe renal impairment (eGFR <30) or in patients on dialysis; use with caution in those populations [7].

Hepatic Impairment

Resmetirom is approved only for compensated MASH (F2, F3). In moderate hepatic impairment (Child-Pugh B), resmetirom AUC increases approximately 2.2-fold. The drug is not recommended in Child-Pugh B or C patients [7]. Patients who progress to cirrhosis (F4) on therapy should have the drug discontinued and be referred for hepatology management, including cirrhosis surveillance protocols per AASLD [5].

Older Adults

MAESTRO-NASH included patients up to age 75. No age-specific dose adjustment was required, but older adults carrying polypharmacy burden need careful interaction review at every visit [4].

Pediatric Patients

Resmetirom has no pediatric approval or data. MASH in adolescents is managed per separate pediatric hepatology guidelines; do not extrapolate adult dosing [7].

Efficacy Benchmarks: What to Expect and When

Prescribers need realistic endpoints to counsel patients and make continuation decisions.

Histologic Endpoints at 52 Weeks (MAESTRO-NASH, N=966)

In MAESTRO-NASH, resmetirom 80 mg produced NASH resolution without fibrosis worsening in 29.9% of patients vs. 9.7% placebo (P<0.0001) [4]. At the 100-mg dose, NASH resolution occurred in 29.9% as well. Fibrosis improvement by one or more stages without NASH worsening was achieved in 24.2% (80 mg) and 25.9% (100 mg) vs. 14.2% placebo (P<0.001 for both doses) [4].

These histologic response rates confirm that roughly 25 to 30% of appropriately selected patients achieve a meaningful fibrosis benefit at one year. Set expectations accordingly: the majority of patients will not show histologic response, and continued therapy in non-responders requires a clinical judgment call pending MAESTRO-NASH OUTCOMES data.

Lipid Response Benchmarks

LDL-C reduction of 15 to 26% and triglyceride reduction of roughly 22 to 30% are expected by week 12 in most patients [9]. Absence of lipid response by week 16 may signal poor adherence, a drug interaction reducing bioavailability, or malabsorption.

Liver Enzyme Trends

ALT typically declines 15 to 30% from baseline in responders within the first 12 weeks. A rising or flat ALT after 24 weeks of therapy, in the absence of competing causes, may indicate inadequate response and should prompt shared decision-making about continuation [4].

Prescriber Checklist: Summary Decision Tool

The following structured checklist consolidates the monitoring bundle into a single workflow for clinic use.

Before First Dose:

• [ ] Confirm F2, F3 fibrosis by biopsy, elastography, or validated composite score
• [ ] Obtain baseline ALT, AST, total bilirubin, ALP, albumin, INR
• [ ] Obtain fasting lipid panel, TSH (reflex free T4), CMP
• [ ] Obtain serology: HBsAg, anti-HCV
• [ ] Obtain right-upper-quadrant ultrasound (gallbladder assessment)
• [ ] Confirm negative pregnancy test (women of childbearing potential)
• [ ] Confirm effective contraception in place (women of childbearing potential)
• [ ] Review CYP2C8 inhibitors/inducers in current medication list
• [ ] Limit rosuvastatin to ≤10 mg/day; check statin type and dose
• [ ] Check warfarin/anticoagulant status; plan INR recheck at week 2 if applicable
• [ ] Assign dose: 80 mg if body weight <100 kg; 100 mg if ≥100 kg

Week 4:

• [ ] ALT, AST, total bilirubin
• [ ] TSH
• [ ] Pregnancy test (monthly, ongoing)
• [ ] Biliary symptom screen

Week 12:

• [ ] Full liver panel + lipid panel
• [ ] TSH with reflex free T4 if TSH suppressed at week 4
• [ ] Adherence review; pill count or pharmacy refill confirmation
• [ ] LDL-C response check; consider statin de-intensification if LDL-C <40 mg/dL

Every 24 Weeks:

• [ ] Full liver panel, lipid panel, HbA1c, fasting glucose
• [ ] TSH (annually once stable)
• [ ] Non-invasive fibrosis imaging as clinically indicated
• [ ] Reassess benefit-risk; document continuation rationale in chart